Derek J. Maetzold is the President and CEO of Castle Biosciences, a company he founded in 2007. With a solid educational background, he holds an MBA from the University of California, Berkeley. Over the years, he has played a vital...

Derek J. Maetzold is the President and CEO of Castle Biosciences, a company he founded in 2007. With a solid educational background, he holds an MBA from the University of California, Berkeley. Over the years, he has played a vital role in bringing innovative diagnostic tools to the market, significantly impacting cancer detection and treatment. In 2023, his total compensation reached approximately $1.6 million, largely due to substantial performance-based bonuses that emphasize the company's success. Maetzold has been very effective in communicating with shareholders and ensuring their interests are aligned with executive decisions. He also actively engages with stakeholders, demonstrating the company’s commitment to transparency and accountability. Interestingly, he possesses over 1 million shares in Castle, showing his vested interest in the company’s future. Maetzold's leadership style is geared towards long-term growth, focusing on achieving corporate performance goals while minimizing risks. This strategic approach has led to impressive revenue growth, setting the company on a clear path toward success in the biotech field.